Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

1 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-05-31

Study Completion Date

2011-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigational Drug:

Ofatumumab (Azerra)

Route of Administration:

Intravenous (IV)

Hypothesis:

This study is designed to assess the toxicity and overall response rate. Ofatumumab is a fully human monoclonal antibody (A type of protein made in the laboratory that can bind to substances in the body, including tumor cells) that shows promising activity in the treatment of CLL as a single agent. It is thought that by combining it with Bendamustine, an FDA approved treatment for CLL, the effect on CLL will be greater than if Ofatumumab is given alone.

Participation:

Approximately 38 previously untreated CLL subjects will participate in this study over two years.

Treatment Plan:

A maximum of 6 cycles of treatment will be allowed. During day 1 of cycle 1 ofatumumab IV 300mg will be administered. On day 1 of all cycles ofatumumab treatment will be followed by bendamustine IV 90mg/m2. On day 2 of all cycles, bendamustine IV 90mg/m2 will be administered. On day 3 of all cycles, neulasta SQ 6mg will be given. On day 8 of cycle 1 only patients will receive ofatumumab IV 1000mg. During cycles 2 through 6 ofatumumab 1000mg will be given on day 1 only.

Follow-up:

Patients will be followed monthly for six months, then every three months for five years then annually thereafter.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

NCT01131247

Chronic Lymphocytic Leukemia (CLL)

WITHDRAWN PHASE2

Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

NCT01010568

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma

TERMINATED PHASE2

Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

NCT01258933

Leukemia Lymphoma

TERMINATED PHASE2

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

NCT02689141

Chronic Lymphocytic Leukemia

COMPLETED PHASE2

Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT01243190

Chronic Lymphocytic Leukemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Lymphocytic Leukemia (CLL)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ofatumumab + bendamustine

Group Type EXPERIMENTAL

ofatumumab + bendamustine

Intervention Type DRUG

Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ofatumumab + bendamustine

Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Generic: Ofatumumab Brand: Arzerra Generic: Bendamustine Brand: Treanda

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be \>/= 18 years old and able to provide consent
* Must have diagnosis of CLL as defined by NCI criteria
* Must be previously untreated for CLL
* Must require chemotherapy
* serum creatinine \<1.8 mg/dl
* Bilirubin must be \</= 2 mg/d, unless secondary to tumor
* Must have adequate liver function (as defined as \<2x ULN, unless related to CLL)
* Performance status 0-2
* Women of child bearing age must be willing to use accepted/effective method of birth control.

Exclusion Criteria

* Not have received prior treatment with cytotoxic chemotherapy or immunotherapy.
* Not have autoimmune hemolytic anemia or autoimmune thrombocytopenia
* Not have history of corticosteroid treatment for CLL
* Not have CNS disease
* Not have clinically significant infections
* Patients with a second malignancy, other than basal cell carcinoma of the skin or in situ carcinoma of the cervix are not eligible.
* Not have positive serology for Hepatitis B or Hepatitis C
* Not have be known to be HIV positive
* Not have New York Classification III or IV hear disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No